Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nasdaq has halted trading of the company’s common stock.
The U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee is meeting virtually today to review the resubmitted NUPLAZID (pimavanserin) supplemental New Drug Application for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.
The Advisory Committee meeting is scheduled for 8:45 a.m. ET. The briefing materials and access to the live video can be found on the FDA’s website here.
The target action date for the application is August 4, 2022.
https://finance.yahoo.com/news/acadia-pharmaceuticals-stock-trading-halted-110500509.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.